Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 9/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ESRRA | P11474 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2091503 | 0.81 | MAPT (0.55) | MAPTHPGDRAB9AMAOBL3MBTL1 | |
| SCHEMBL1439934 | 0.77 | AURKA (0.34) | ALDH1A1TSHRHSD17B10 | |
| SCHEMBL2457021 | 0.76 | NOTUM (0.38) | MAPTHPGDL3MBTL1GAALMNA | |
| SCHEMBL9006596 | 0.76 | MAPT (0.53) | MAPTHPGDRAB9AMAOBL3MBTL1 | |
| SCHEMBL15711798 | 0.75 | ALDH1A1 (0.43) | MAPTHPGDRAB9AMAOBL3MBTL1 | |
| SCHEMBL15675600 | 0.74 | ALDH1A1 (0.44) | MAPTHPGDRAB9AMAOBL3MBTL1 | |
| SCHEMBL15675525 | 0.74 | ALDH1A1 (0.39) | MAPTHPGDRAB9AMAOBL3MBTL1 | |
| SCHEMBL75853 | 0.73 | RAB9A (0.59) | MAPTHPGDRAB9AMAOBL3MBTL1 | |
| SCHEMBL12330843 | 0.73 | KAT6A (0.36) | MAOBLMNAHTT | |
| SCHEMBL9578574 | 0.73 | TSHR (0.56) | ALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150361030-A1 | PERFLUOROPOLYVINYL MODIFIED ARYL INTERMEDIATES AND MONOMERS | DU PONT (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150361030-A1 | PERFLUOROPOLYVINYL MODIFIED ARYL INTERMEDIATES AND MONOMERS | DU PONT (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150361030-A1 | PERFLUOROPOLYVINYL MODIFIED ARYL INTERMEDIATES AND MONOMERS | DU PONT (US) | 2015-12-17 | — | — | US | disclosed |
| US-9145356-B2 | Perfluoropolyvinyl modified aryl intermediates and monomers | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145356-B2 | Perfluoropolyvinyl modified aryl intermediates and monomers | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145356-B2 | Perfluoropolyvinyl modified aryl intermediates and monomers | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| EP-2920140-A1 | PERFLUOROPOLYVINYL MODIFIED ARYL INTERMEDIATES AND MONOMERS | E. I. du Pont de Nemours and Company (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014078173-A1 | PERFLUOROPOLYVINYL MODIFIED ARYL INTERMEDIATES AND MONOMERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20140135518-A1 | PERFLUOROPOLYVINYL MODIFIED ARYL INTERMEDIATES AND MONOMERS | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135518-A1 | PERFLUOROPOLYVINYL MODIFIED ARYL INTERMEDIATES AND MONOMERS | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135518-A1 | PERFLUOROPOLYVINYL MODIFIED ARYL INTERMEDIATES AND MONOMERS | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361030-A1 | PERFLUOROPOLYVINYL MODIFIED ARYL INTERMEDIATES AND MONOMERS | AFF1, AFF2, FOS | MAPT 4173/4885HPGD 4041/4885RAB9A 1725/4885 |
| US-20140135518-A1 | PERFLUOROPOLYVINYL MODIFIED ARYL INTERMEDIATES AND MONOMERS | AFF1, FOS, AFF2 | MAPT 4191/4885HPGD 4015/4885RAB9A 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.